Inspire Medical Systems, Inc. (INSP) announced on Friday that it has received FDA approval for its next-generation Inspire V therapy system, designed to treat moderate to severe obstructive sleep apnea.
The Inspire V therapy system introduces a new neurostimulator, along with a Bluetooth-enabled patient remote and a physician programmer.
The company revealed plans for a soft launch in late 2024, with a full-scale launch anticipated in 2025 in the U.S. market.
As of pre-market activity on the NYSE, shares are trading at $137.90, reflecting a 4.97% increase.
